KemPharm, Inc. (KMPH): Price and Financial Metrics

KemPharm, Inc. (KMPH)

Today's Latest Price: $0.98 USD

0.04 (-3.69%)

Updated Dec 2 3:59pm

Add KMPH to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

KMPH Stock Summary

  • Kempharm Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7.09% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -0.16 for Kempharm Inc; that's greater than it is for only 7.09% of US stocks.
  • The volatility of Kempharm Inc's share price is greater than that of 95.19% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to KMPH, based on their financial statements, market capitalization, and price volatility, are APM, LJPC, MTSI, VBIV, and FBIO.
  • KMPH's SEC filings can be seen here. And to visit Kempharm Inc's official web site, go to

KMPH Stock Price Chart Interactive Chart >

Price chart for KMPH

KMPH Price/Volume Stats

Current price $0.98 52-week high $1.38
Prev. close $1.02 52-week low $0.12
Day low $0.95 Volume 995,078
Day high $1.15 Avg. volume 1,715,695
50-day MA $0.69 Dividend yield N/A
200-day MA $0.44 Market Cap 70.91M

KemPharm, Inc. (KMPH) Company Bio

KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of prodrugs to treat high need areas of pain, ADHD and other CNS disorders. The company was founded in 2006 and is based in Coralville, Iowa.

KMPH Latest News Stream

Event/Time News Detail
Loading, please wait...

KMPH Latest Social Stream

Loading social stream, please wait...

View Full KMPH Social Stream

Latest KMPH News From Around the Web

Below are the latest news stories about Kempharm Inc that investors may wish to consider to help them evaluate KMPH as an investment opportunity.

KemPharm, Inc. (KMPH) CEO Travis Mickle on Q2 2020 Results - Earnings Call Transcript

KemPharm, Inc. (KMPH) Q2 2020 Results Conference Call August 12, 2020 4:30 PM ET Company Participants Jason Rando - Tiberend Strategic Advisors, Inc. Travis Mickle - President & CEO LaDuane Clifton - CFO Conference Call Participants Oren Livnat - H.C. Wainwright Presentation Operator Ladies and gentlemen, thank you for standing...

SA Transcripts on Seeking Alpha | August 12, 2020

KemPharm issued new U.S. patents for SDX-based product candidates

KemPharm (KMPH) announces that the United States Patent and Trademark Office, has issued two new patents covering methods of use and composition of matter for KP415 and KP484, prodrug of d-methylphenidate serdexmethylphenidate ((SDX)).New patent issuance extends SDX patent life for an additional 5 year until 2037KP415 and KP484 are under development for...

Seeking Alpha | July 28, 2020

Edited Transcript of KMPH earnings conference call or presentation 12-May-20 9:00pm GMT

Q1 2020 KemPharm Inc Earnings Call

Yahoo | June 22, 2020

KemPharm Issues Letter to Shareholders

KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders in connection with the Company’s 2020 Annual Meeting of Stockholders to be held on June 19, 2020. The last twelve months have been a period of significant advancement for KemPharm. Just recently, the New Drug Application (“NDA”) for KP415, our investigational product candidate for the treatment of attention deficit hyperactivity disorder (“ADHD”), was successfully filed and accepted by the U.S. Food and Drug Administration (“FDA”).

Yahoo | June 18, 2020

KemPharm Receives Day-74 Letter for KP415 NDA

KemPharm, Inc. (KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today confirmed that the Company has received a filing communication from the U.S. Food and Drug Administration (FDA), commonly known as the “Day-74 Letter.” The Day-74 Letter stated that the New Drug Application (NDA) for KP415 is sufficiently complete to permit a substantive review by the FDA, and that the target goal date under the Prescription Drug User Fee Act (PDUFA) is March 2, 2021. In addition, the Day-74 Letter indicated that the FDA is not currently planning to hold an advisory committee to discuss the KP415 NDA.

Yahoo | May 19, 2020

Read More 'KMPH' Stories Here

KMPH Price Returns

1-mo 59.35%
3-mo 42.03%
6-mo 441.44%
1-year 133.44%
3-year -74.04%
5-year -94.22%
YTD 158.37%
2019 -78.69%
2018 -56.05%
2017 37.29%
2016 -85.15%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9919 seconds.